About Madhavi Taneja

Madhavi is a seasoned financial analyst with a focus in valuing early-stage technology companies and evaluating potential mergers and acquisitions. After majoring in economics, she developed a deep understanding of investment strategies while working with EX Service. Fundamental analysis is Madhavi’s forté and her goal is to help others achieve their investing goals. Along with parenting her four-year old daughter, she is passionate about continuing to advance her knowledge and understanding of all things relating to finance and investing.

Recent Articles By Madhavi Taneja

: NFLX |  News, Ratings, and Charts

3 High-Flying Stocks Setting Up for BIG MOVES This Earnings Season

The skyrocketing stock market has sent many stocks at their all-time highs this year. These stocks are seeing revenues accelerate due to the coronavirus. Earnings season will tell us whether this momentum is continuing. Stocks likeTesla (TSLA) Netflix (NFLX), and Peloton Interactive (PTON), are looking set to make new highs.  
: NFLX |  News, Ratings, and Charts

Will Shares of Netflix Continue to Soar in 2021?

With its strong growth in subscribers and an array of original content, Netflix (NFLX) is well positioned to take advantage of the coronavirus pandemic-driven opportunities and generate high returns for its investors in the upcoming quarters.
: AMGN |  News, Ratings, and Charts

4 Top Biotech Stocks to Buy for the Remainder of 2020

With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are four worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB).
: TWTR |  News, Ratings, and Charts

Will Twitter's Stock Continue to Surge Higher?

Twitter (TWTR) has boasted double-digit gains year-to-date as a result of the social media industry’s growing popularity amid the coronavirus pandemic. The stock’s growth momentum is expected to continue in the upcoming months, given its short-and-long-term bullishness, impressive financials and underlying industry strength.
: MSFT |  News, Ratings, and Charts

4 Work From Home Stocks Poised to Climb into Next Year

The coronavirus is still with us, and it’s expected to get worse during the winter. It will likely facilitate a permanent increase in the number of companies and people working from home. This will benefit companies like Microsoft (MSFT), Zoom (ZM), Wayfair (W), and Okta (OKTA) that provide the infrastructure for remote work.
: APHA |  News, Ratings, and Charts

Is Aphria a Buy Under $7?

Certain industries are outperforming as the market is anticipating a change in regulation under a new political regime. Current polling shows that Democrats are favored to take control of the Senate, and former VP Joe Biden is a 65% favorite to win the election. One result will be the more favorable treatment of cannabis. Aphira (APHA) would certainly see big gains as a result. 
: HBI |  News, Ratings, and Charts

3 Cheap Dividend Stocks to Buy for the Rest of 2020

The uncertainty created by the presidential election and fiscal stimulus talks have led to market volatility. For investors looking for more stable income opportunities and the potential for capital appreciation, these three stocks are worth a look: Hanesbrands (HBI), Rent-a-Center (RCII), and OneMain Holdings (OMF).
: KO |  News, Ratings, and Charts

Is Coca-Cola's Stock a Good Buy?

Even though the pandemic has adversely affected Coca-Cola (KO), there is no denying that it still remains one of the favorite stocks for dividend investors. It is well positioned to make a comeback based on the recovery in demand for home consumption, short-and-long term bullishness and underlying financial strength.
: VZ |  News, Ratings, and Charts

3 Value Stocks with 4% PLUS Yields

As the upcoming presidential election and uncertainty over stimulus measures are expected to keep the market volatile in the coming months, reasonably priced dividend stocks like Verizon Communications (VZ), Philip Morris International (PM), and Pfizer (PFE) could steady income and the potential for price appreciation.
: AMGN |  News, Ratings, and Charts

4 Biotech Stocks to Buy for 2021

With huge investments being made in the biotech industry thanks to the pandemic, it’s an opportune time to consider investing in the industry, Here are four stocks worth a look: Amgen (AMGN), Immunomedics (IMMU), Trevena (TRVN), abd Celldex Therapeutics (CLDX).
Page generated in 0.6872 seconds.